Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?
作者信息
AlAkhras Abdullah, AlMessabi Ahmed Husein, Abuzeid Hala, Khoo Saye, Nsutebu Emmanuel Fru
机构信息
Internal Medicine Department, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates.
Infectious Disease Division, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates.
出版信息
Postgrad Med J. 2020 Jul;96(1137):377-378. doi: 10.1136/postgradmedj-2020-137990. Epub 2020 May 21.
Abstract
摘要
相似文献
1
Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?用于治疗新冠肺炎的特定抗菌药物：我们现在就应该开这些药还是等待更多证据？
Postgrad Med J. 2020 Jul;96(1137):377-378. doi: 10.1136/postgradmedj-2020-137990. Epub 2020 May 21.
2
A Trial of Lopinavir-Ritonavir in Covid-19.洛匹那韦-利托那韦治疗新冠肺炎的试验
N Engl J Med. 2020 May 21;382(21):e68. doi: 10.1056/NEJMc2008043. Epub 2020 May 5.
3
A Trial of Lopinavir-Ritonavir in Covid-19.洛匹那韦-利托那韦治疗新冠肺炎的试验
N Engl J Med. 2020 May 21;382(21):e68. doi: 10.1056/NEJMc2008043. Epub 2020 May 5.
4
A Trial of Lopinavir-Ritonavir in Covid-19.洛匹那韦-利托那韦治疗新冠肺炎的试验
N Engl J Med. 2020 May 21;382(21):e68. doi: 10.1056/NEJMc2008043. Epub 2020 May 5.
5
A Trial of Lopinavir-Ritonavir in Covid-19.洛匹那韦-利托那韦治疗新冠肺炎的试验
N Engl J Med. 2020 May 21;382(21):e68. doi: 10.1056/NEJMc2008043. Epub 2020 May 5.
6
A Trial of Lopinavir-Ritonavir in Covid-19.洛匹那韦-利托那韦治疗新冠病毒病的一项试验
N Engl J Med. 2020 May 21;382(21):e68. doi: 10.1056/NEJMc2008043. Epub 2020 May 5.
7
Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir.洛匹那韦利托那韦治疗的 2 例 COVID-19 患者出现血清素综合征。
J Neurol Sci. 2020 Aug 15;415:116944. doi: 10.1016/j.jns.2020.116944. Epub 2020 May 27.
8
Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?洛匹那韦/利托那韦用于新冠肺炎患者：也许可以，但用什么剂量呢？
J Antimicrob Chemother. 2020 Sep 1;75(9):2704-2706. doi: 10.1093/jac/dkaa190.
9
A Trial of Lopinavir-Ritonavir in Covid-19. Reply.洛匹那韦-利托那韦治疗新冠肺炎的试验。回复。
N Engl J Med. 2020 May 21;382(21):e68. doi: 10.1056/NEJMc2008043. Epub 2020 May 5.
10
Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).洛匹那韦和利托那韦在2019冠状病毒病（COVID-19）住院患者中的药代动力学
Ann Intern Med. 2020 Oct 20;173(8):670-672. doi: 10.7326/M20-1550. Epub 2020 May 12.
引用本文的文献
1
COVID-19 and Antimicrobial Resistance: A Review.新型冠状病毒肺炎与抗菌药物耐药性：综述
Infect Dis (Auckl). 2021 Jul 31;14:11786337211033870. doi: 10.1177/11786337211033870. eCollection 2021.
2
Safety Consequences of Off-Label Drugs Used for COVID-19.用于治疗新冠肺炎的超说明书用药的安全性后果。
Drug Saf. 2021 Apr;44(4):399-402. doi: 10.1007/s40264-021-01056-0. Epub 2021 Mar 5.
3
Drug repurposing for COVID-19: a potential threat of self-medication and controlling measures.新冠病毒病的药物再利用：自我用药的潜在风险及管控措施
Postgrad Med J. 2021 Nov;97(1153):742-743. doi: 10.1136/postgradmedj-2020-138447. Epub 2020 Aug 26.
本文引用的文献
1
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
2
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
3
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.一项关于氯喹治疗 COVID-19 的疗效和安全性的系统评价。
J Crit Care. 2020 Jun;57:279-283. doi: 10.1016/j.jcrc.2020.03.005. Epub 2020 Mar 10.
4
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.2019 冠状病毒病（COVID-19）疫情的起源、传播和临床治疗——现状更新。
Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
5
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
6
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）和 2019 年冠状病毒病（COVID-19）：疫情和挑战。
Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. Epub 2020 Feb 17.
7
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
8
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
Zotero 插件